What is Kneat?
Kneat Solutions specializes in the development of Kneat Gx, a sophisticated cloud-based platform engineered for validation lifecycle management. The software is purpose-built for highly regulated sectors, including pharmaceutical, biotechnology, and medical device manufacturing. By digitizing and automating complex workflows such as commissioning, qualification, and quality assurance, Kneat provides a centralized source of truth that enhances data integrity and simplifies regulatory oversight. The platform is designed to address the specific pain points of life sciences organizations, offering a scalable architecture that supports global compliance requirements and operational excellence in an increasingly digital-first regulatory landscape.
How much funding has Kneat raised?
Kneat has raised a total of $51M across 4 funding rounds:
Stock Offering
$12.7M
Stock Offering
$20M
Share Placement
$2M
Debt
$16.3M
Stock Issuance/Offering (2020): $12.7M, investors not publicly disclosed
Stock Issuance/Offering (2021): $20M, investors not publicly disclosed
Share Placement (2021): $2M, investors not publicly disclosed
Debt (2023): $16.3M featuring IPF Partners
Key Investors in Kneat
IPF Partners
IPF Partners is a specialized alternative financing provider focused exclusively on the healthcare sector, offering tailored debt and equity solutions for commercial-stage biopharma and medtech companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Kneat?
Looking ahead, the strategic deployment of this recent funding will likely focus on expanding Kneat's global footprint and enhancing its core software capabilities. With the life sciences industry facing mounting pressure to improve efficiency without compromising on safety or compliance, Kneat is well-positioned to capture additional market share. The company is expected to prioritize the integration of advanced analytics and automated reporting features within its Gx platform, further reducing the time-to-market for critical therapies. By maintaining its focus on high-growth segments and deepening its relationships with enterprise-level clients, Kneat is poised to remain at the forefront of the regulatory technology sector, driving long-term value through sustained innovation and strategic market expansion.
See full Kneat company page
